You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

New Horizons and Expert Insights on the Management of Recurrent Clostridioides difficile Infection

  • Authors: Carl V. Crawford, MD; Jessica Allegretti, MD, MPH, AGAF, FACG; Kevin W. Garey, PharmD, FIDSA
  • CME / ABIM MOC / CE Released: 5/31/2023
  • Valid for credit through: 5/31/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    IPCE - 1.00 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, infectious disease specialists, primary care physicians, and pharmacists.

The goal of this activity is for learners to be better able to incorporate microbiome-directed therapies, including live biotherapeutics, into the management of recurrent CDI.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of antibiotic-induced dysbiosis in the pathophysiology of recurrent CDI
    • Latest clinical data on emerging and newly approved microbiome-directed therapies for prevention of recurrent CDI
  • Have greater competence related to
    • Implementation of evidence-based therapies in the management of recurrent CDI
  • Demonstrate greater confidence in their ability to
    • Incorporate newly approved and emerging biotherapeutic agents in their treatment approach for patients with recurrent CDI


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Carl V. Crawford, MD

    Assistant Professor of Clinical Medicine
    Program Director
    Gastroenterology and Hepatology Fellowship
    Weill Cornell Medical College
    New York, New York

    Disclosures

    Carl V. Crawford, MD, has the following relevant financial relationships:
    Consultant or advisor for: Ferring Pharmaceuticals; Seres
    Speaker or member of speakers bureau for: Ferring Pharmaceuticals; Merck & Co., Inc.
    Research funding from: Artugen Therapeutics; Ferring Pharmaceuticals
    Owns stock (publicly traded) in: Merck & Co., Inc.; Seres

  • Kevin W. Garey, PharmD, FIDSA

    Professor of Pharmacy Practice
    Department Chair
    Pharmacy Practice and Translational Research
    University of Houston College of Pharmacy
    Houston, Texas

    Disclosures

    Kevin W. Garey, PharmD, FIDSA, has the following relevant financial relationships:
    Research funding from: Acurx Pharmaceuticals; Paratek Pharmaceuticals; SERES Health; Summit

  • Jessica R. Allegretti, MD, MPH, AGAF, FACG

    Associate Professor of Medicine
    Harvard Medical School
    Director, Crohn’s and Colitis Center
    Director, Fecal Microbiota Transplant Program
    Brigham & Women’s Hospital
    Boston, Massachusetts

    Disclosures

    Jessica R. Allegretti, MD, MPH, AGAF, FACG, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Bristol-Myers Squibb Company; Finch Therapeutics; Janssen Pharmaceuticals; Iterative Scopes; Lilly; Merck & Co., Inc.; Pfizer Inc.; Seres
    Speaker or member of speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company
    Research funding from: Janssen Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.
    Contracted researcher for: Artugen Therapeutics; Amgen Inc.; Finch Therapeutics; Janssen Pharmaceuticals; Pfizer Inc.

Editor

  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Roderick Smith, MS, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-217-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

New Horizons and Expert Insights on the Management of Recurrent Clostridioides difficile Infection

Authors: Carl V. Crawford, MD; Jessica Allegretti, MD, MPH, AGAF, FACG; Kevin W. Garey, PharmD, FIDSAFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/31/2023

Valid for credit through: 5/31/2024, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print